Welcome to the Hergenrother Lab!
With a guiding theme of using chemistry and small-molecules to identify, explore, and define novel targets for the treatment of disease, we aspire to make an impact in both chemistry and biology. We are both chemists and biologists, using the scientific techniques necessary to solve complex disease-driven questions.
In the Hergenrother lab, we are fully committed to fostering a culture of diversity, inclusion, and equity in our lab and department. Our group welcomes all people with talent of all racial, cultural, and socioeconomic backgrounds, sexual orientations, and gender expressions to join us in our pursuit of scientific discovery. We pledge to be supportive of all individuals and maintain a collaborative and inclusive environment
Hergenrother Lab News:
A Phase 1B/2 clinical trial of PAC-1 for patients with metastatic uveal melanoma is now enrolling
A compound for breast cancer discovered and developed in the Hergenrother and Shapiro labs has been licensed to Bayer.
Congratulations to graduate student Matthew Boudreau who has been awarded a prestigious F99/K00 Award from the NCI!
Congratulations to Dr. Steven Motika for being awarded a postdoctoral fellowship from the NIH!
Congratulations to Matthew Boudreau for being awarded a predoctoral fellowship from the Medicinal Chemistry division of the ACS!
See story on Pretzel, a pet dog with glioma successfully treated with PAC-1.
eNTRyway, our web app for predicting compound accumulation in Gram-negative bacteria, is live!